Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Distler

Showing results (281-290 of 621) with videos related to

Pageof 63
Sort By:
Arthritis and Rheumatism|December 30, 2009
The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosisNicole Reich, Britta Maurer, Alfiya Akhmetshina, et al.
Annals of the Rheumatic Diseases|February 14, 2012
β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosisChristian Beyer, Amelie Schramm, Alfiya Akhmetshina, et al.
Annals of the Rheumatic Diseases|November 12, 2014
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expressionNaoki Iwamoto, Serena Vettori, Britta Maurer, et al.
Arthritis and Rheumatism|December 30, 2009
Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyOliver Distler, Wolfgang Eich, Eva Dokoupilova, et al.
Arthritis and Rheumatism|May 18, 2004
Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritisAstrid Jüngel, Jörg H W Distler, Mariola Kurowska-Stolarska, et al.
Arthritis and Rheumatism|September 2, 2008
The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosisSerena Guiducci, Jörg H W Distler, Astrid Jüngel, et al.
Neurogastroenterology and Motility|October 3, 2018
Abnormal esophageal motility during a solid test meal in systemic sclerosis-detection even in very early disease and association with disease progressionSimon Bütikofer, Suzana Jordan, Matthias Sauter, et al.
Clinical and Experimental Rheumatology|July 1, 2017
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)Oliver Distler, Kevin K Brown, Jörg H W Distler, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
Arthritis and Rheumatism|May 3, 2012
JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosisClara Dees, Michal Tomcik, Katrin Palumbo-Zerr, et al.
Pageof 63

Showing results (281-290 of 621) with videos related to

Sort By:
Pageof 63
Arthritis and Rheumatism|December 30, 2009
The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosisNicole Reich, Britta Maurer, Alfiya Akhmetshina, et al.
Annals of the Rheumatic Diseases|February 14, 2012
β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosisChristian Beyer, Amelie Schramm, Alfiya Akhmetshina, et al.
Annals of the Rheumatic Diseases|November 12, 2014
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expressionNaoki Iwamoto, Serena Vettori, Britta Maurer, et al.
Arthritis and Rheumatism|December 30, 2009
Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyOliver Distler, Wolfgang Eich, Eva Dokoupilova, et al.
Arthritis and Rheumatism|May 18, 2004
Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritisAstrid Jüngel, Jörg H W Distler, Mariola Kurowska-Stolarska, et al.
Arthritis and Rheumatism|September 2, 2008
The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosisSerena Guiducci, Jörg H W Distler, Astrid Jüngel, et al.
Neurogastroenterology and Motility|October 3, 2018
Abnormal esophageal motility during a solid test meal in systemic sclerosis-detection even in very early disease and association with disease progressionSimon Bütikofer, Suzana Jordan, Matthias Sauter, et al.
Clinical and Experimental Rheumatology|July 1, 2017
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)Oliver Distler, Kevin K Brown, Jörg H W Distler, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
Arthritis and Rheumatism|May 3, 2012
JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosisClara Dees, Michal Tomcik, Katrin Palumbo-Zerr, et al.
Pageof 63